Drug Pricing Stewardship from Mark Cuban's Cost Plus Generic Drug Program

Area of Science:

• Health Economics
• Pharmaceutical Policy
• Healthcare Management

Background:

• US prescription drug spending is high, partly due to inefficient generic drug distribution and reimbursement.
• Potential savings and intervention areas for generic drug prescribers are not well understood.

Purpose of the Study:

• To analyze 2021 Medicare Part D generic drug spending.
• To compare this spending with pricing from the Mark Cuban Cost Plus Drug Company (MCCPDC).
• To estimate potential achievable savings.

Main Methods:

• Retrospective, observational study analyzing Medicare Part D data (2021) and MCCPDC pricing (August 2023).
• Systematic analysis of potential savings using MCCPDC generic pricing.
• Outcomes included prescription volume, proportion of drugs with savings, total Medicare savings, and price reduction per unit, stratified by medical/surgical subspecialties.

Main Results:

• Estimated Medicare Part D savings of $8.6 billion using 90-day MCCPDC pricing.
• Surgical drugs contributed over $900 million to potential savings.
• Nearly 80% of drugs were cheaper via MCCPDC; highest absolute savings in cardiology, psychiatry, neurology, transplant, and urology.
• Disproportionate savings relative to volume seen in oncology, gynecology, infectious disease, transplant surgery, and colorectal surgery.

Conclusions:

• Significant Medicare Part D savings are possible by addressing systemic overpayments for generic medications.
• Identified key areas for reform in generic drug pricing and distribution.
• Specific medical and surgical subspecialties are prime targets for interventions to achieve substantial savings.